Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells

Journal of Nutritional Science and Vitaminology

Volumn 53, Issue 6, 2007, Pages 556-560

  Harada, Naoki ^a   Murata, Yohei ^a   Yamaji, Ryoichi ^a   Miura, Takumi ^a   Inui, Hiroshi ^a   Nakano, Yoshihisa ^a  

^a Osaka Prefecture University   (Japan)

Author keywords

Androgen receptor; Phytoestrogen; Prostate cancer; Resveratrol

Indexed keywords

ANDROGEN RECEPTOR; CYCLOHEXIMIDE; RESVERATROL;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MUTANT; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; STILBENES;

EID: 38549098099     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.53.556     Document Type: Article

References (23)

1. Hain R, Bieseler B, Kindl H, Schroder G, Stocker R. 1990. Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant Mol Biol 15: 325-335.
2. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
3. Jang DS, Kang BS, Ryu SY, Chang IM, Min KR, Kim Y. 1999. Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem Pharmacol 57: 705-712.
4. Fremont L, Belguendouz L, Delpal S. 1999. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci 64: 2511-2521.
5. Gao S, Liu GZ, Wang Z. 2004. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 59: 214-225.
6. Mgbonyebi OP, Russo J, Russo IH. 1998. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865-869.
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. 2006. Cancer statistics, 2006. CA Cancer J Clin 56: 106-130.
8. Brinkmann AO, Farber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst MM, van Laar JH, Mulder E. 1989. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem 34: 307-310.
9. Pratt WB, Toft DO. 1997. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18: 306-360.
10. Bowers JL, Tyulmenkov W, Jernigan SC, Klinge CM. 2000. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141: 3657-3667.
11. Mitchell SH, Zhu W, Young CYF. 1999. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59: 5892-5895.
12. Yuan H, Pan Y, Young CYF. 2004. Overexpression of c-Jun induced by quercetin and resveratrol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 213: 155-163.
13. Harada N, Yasunaga R, Higashimura Y, Yamaji R, Fujimoto K, Moss J, Inui H, Nakano Y. 2007. Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells. J Biol Chem 282: 22651-22661.
14. Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM. 1994. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. J Biol Chem 269: 13115-13123.
15. Jenster G, van der Korput HA, Trapman J, Brinkmann AO. 1995. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 270: 7341-7346.
16. Wong C, Kelce WR, Sar M, Wilson EM. 1995. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 270: 19998-20003.
17. Kemppainen JA, Lane MV, Sar M, Wilson EM. 1992. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267: 968-974.
18. Furutani T, Watanabe T, Tanimoto K, Hashimoto T, Koutoku H, Kudoh M, Shimizu Y, Kato S, Shikama H. 2002. Stabilization of androgen receptor protein is induced by agonist, not by antagonists. Biochem Biophys Res Commun 294: 779-784.
19. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H. 2004. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor β. Eur Urol 45: 245-251.
20. Xing N, Chen Y, Mitchell SH, Young CYF. 2001. Quercetin inhibits the expression and function of the androgen recptor in LNCaP prostate cancer cells. Carcinogenesis 22: 409-414.
21. Sheflin L, Keegan B, Zhang W, Spaulding SW. 2000. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276: 144-150.
22. Lin HK, Hu YC, Lee DK, Chang C. 2004. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 18: 2409-2423.
23. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP. 1997. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319.